Acute Myeloid Leukemia, Adult
Welcome,         Profile    Billing    Logout  
 183 Companies   238 Products   238 Products   105 Mechanisms of Action   9 Trials   2018 News 


12345678910111213...4142»
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Enrollment change, Trial termination:  Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=20, Terminated, 
    Active, not recruiting --> Completed N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
  • ||||||||||  Trial completion, Phase classification:  Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) -  Jan 24, 2019   
    P1,  N=90, Completed, 
    Suspended --> Completed | N=60 --> 13 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
  • ||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) -  Jan 15, 2019   
    P2,  N=11, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion, Trial completion date, Trial primary completion date:  WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) -  Nov 30, 2018   
    P2,  N=22, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Aug 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018
  • ||||||||||  lenalidomide / Generic mfg.
    Enrollment change, Trial termination:  Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) -  Oct 18, 2018   
    P2,  N=32, Terminated, 
    Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  DC Vaccination for Postremission Therapy in AML (clinicaltrials.gov) -  Oct 12, 2018   
    P1/2,  N=13, Completed, 
    N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy Recruiting --> Completed | N=20 --> 13 | Trial completion date: Apr 2019 --> Sep 2018 | Trial primary completion date: May 2017 --> Mar 2018
  • ||||||||||  CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) -  Oct 2, 2018   
    P1/2,  N=7, Completed, 
    Completed --> Terminated Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
    Phase classification, Enrollment change, Trial termination:  Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) -  Aug 23, 2018   
    P1,  N=7, Terminated, 
    N=52 --> 25 | Active, not recruiting --> Terminated Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
  • ||||||||||  cyclophosphamide / Generic mfg.
    Phase classification, Trial termination:  Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) -  Aug 20, 2018   
    P1,  N=14, Terminated, 
    Active, not recruiting --> Completed Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual
  • ||||||||||  Vonjo (pacritinib) / CTI BioPharma
    Trial completion date, Trial suspension, Trial primary completion date:  Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (clinicaltrials.gov) -  Jul 26, 2018   
    P1,  N=60, Suspended, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018 Trial completion date: May 2018 --> Sep 2018 | Recruiting --> Suspended | Trial primary completion date: May 2018 --> Sep 2018
  • ||||||||||  cytarabine / Generic mfg.
    Enrollment change, Trial termination:  Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior (clinicaltrials.gov) -  Jul 17, 2018   
    P2/3,  N=10, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018 N=40 --> 10 | Recruiting --> Terminated; Low accrual
  • ||||||||||  plerixafor / Generic mfg., decitabine / Generic mfg.
    Trial completion:  Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) (clinicaltrials.gov) -  Jul 2, 2018   
    P1,  N=71, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  CYAD-01 / Celdara Medical, Celyad Oncology
    Trial completion, Trial primary completion date, Metastases:  Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) -  Jun 3, 2018   
    P1,  N=12, Completed, 
    Active, not recruiting --> Completed | N=90 --> 48 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018